Berita Terbaru             -  INFORMASI AWAL UNTUK TENAGA PROFESIONAL KESEHATAN TERKAIT KEAMANAN PRODUK YANG MENGANDUNG BAHAN AKTIF RANITIDIN            -  INFORMASI AWAL UNTUK TENAGA PROFESIONAL KESEHATAN TERKAIT KEAMANAN PRODUK YANG MENGANDUNG BAHAN AKTIF RANITIDIN            -  Tecentriq (Atezolizumab) and New Important Identified Risk of Immune-Related Myositis            -  Actemra® (Tocilizumab) and Risk of Hepatotoxicity            -  Buletin Berita MESO Volume 37, No 1 Edisi Juni 2019

 

Yellow Form
(ADR Report Form) - Form for Adverse Drug Reaction from Healthcare Professional
   
ADR Online
Adverse Drug Reactions.

Welcome Subsite E-MESO

As we know, that in line with the fast development of technology, the need of information and its access by public is also emerging, including access to drug safety  information. This sub site is designed to providing information on drug safety and pharmacovigilance activities. One of menu in this subsite is ADR Report. This menu allows healthcare professionals (HCPs) and pharmaceutical industries to submit ARDs reports to NADFC electronically. To participate in ADRs reporting using the menu of this subsite, HCPs or pharmaceutical industries shall register or subscribe first.


Read More

Buletin Berita Meso

Buletin Berita MESO Volume 37, No 1 Edisi Juni 2019
26 Jun 2019

Buletin Berita MESO Volume 36, No 2 Edisi November 2018
21 Dec 2018

ADR Bulletin Volume 36, No 1 Edition June 2018
07 Jun 2018

How do you think the content and appearance of this website?




logo dsras Email Rapid Alert System

Selamat email anda telah berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia.

 

logo dsras Email Rapid Alert System

Anda ingin berhenti berlangganan untuk selalu mendapatkan informasi terkini mengenai keamanan obat yang beredar di Indonesia?